Wire · opportunities
[Reporter's Notebook] K-biopharma licensing deals are getting better, not just bigger
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
Korean biopharma licensing deals in 2026 are distinguished by larger upfront payments, repeated licensing of the same platforms, and increasing conversion of deals into products generating sales milestones and royalties, signalling a move towards healthier and more sustainable business models.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prioritise securing larger upfront payments and building repeatable technology platforms that attract multiple deals. This shift reduces reliance on milestone-heavy structures and opens routes to steady commercial revenue beyond initial licensing agreements.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics